Literature DB >> 7488150

Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension.

S Kojima1, T Inui, H Muramatsu, T Kimura, S Sakakibara, T Muramatsu.   

Abstract

We studied about the physicochemical stability of a novel heparin-binding growth/differentiation factor, midkine (MK). It was found that synthetic human MK was heat and acid stable. Neither incubation at 80 degrees C for 90 sec nor treatment at low pH affected the elution profile of MK molecule on the high performance liquid chromatography. This physicochemical stability was maintained in the biological activities of MK to enhance plasminogen activator (PA) activity in bovine endothelial cells as well as to promote neurite outgrowth of rat brain cells. A similar stability was observed both with recombinant murine MK and with its homologous protein, recombinant human pleiotrophin. Comparison of physicochemical stability with other several growth factors suggested that MK/pleiotrophin was a unique family of heat and acid stable polypeptides capable of enhancing PA activity and neurite outgrowth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488150     DOI: 10.1006/bbrc.1995.2661

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

2.  Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus.

Authors:  A M Schulte; S Lai; A Kurtz; F Czubayko; A T Riegel; A Wellstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin.

Authors:  F Czubayko; A M Schulte; G J Berchem; A Wellstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Novel neuronal effects of midkine on embryonic cerebellar neurons examined using a defined culture system.

Authors:  M Matsuzawa; T Muramatsu; T Yamamori; W Knoll; R Yano
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

5.  Solution structure of midkine, a new heparin-binding growth factor.

Authors:  W Iwasaki; K Nagata; H Hatanaka; T Inui; T Kimura; T Muramatsu; K Yoshida; M Tasumi; F Inagaki
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

6.  Structure and phylogenetic analysis of an endogenous retrovirus inserted into the human growth factor gene pleiotrophin.

Authors:  A M Schulte; A Wellstein
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

8.  Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Authors:  Misato Takagi-Kimura; Tomoki Yamano; Atsuko Tamamoto; Nobutaka Okamura; Haruki Okamura; Tomoko Hashimoto-Tamaoki; Masatoshi Tagawa; Noriyuki Kasahara; Shuji Kubo
Journal:  Cancer Sci       Date:  2013-09-23       Impact factor: 6.716

9.  A quantitative bioassay for nerve growth factor, using PC12 clones expressing different levels of trkA receptors.

Authors:  Itzhak Katzir; Jashovam Shani; Keren Regev; Dalia Shabashov; Philip Lazarovici
Journal:  J Mol Neurosci       Date:  2002-06       Impact factor: 3.444

10.  Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.